I agree with nearly everything you said. I also b
Post# of 30067
(Total Views: 346)
Posted On: 06/18/2017 8:45:14 PM
Re: investorxc #24983
I agree with nearly everything you said. I also bought in before CHF. The more I have learned about CHF, the more skeptical I am. I certainly don't think he cares about current AMBS shareholders. Dude just cares about his own bank account and whether he thinks he can pilfer Amarantus because the company is in absolute desperate times. I suspect he sees AMBS as some sort of quick venture - much like he tried to market HotApp as a $700M company akin to WhatsApp after he bought it for 90k and then tried to go public and failed miserably. Guy is a shady penny stock vulture. Anyone who denies that is just kidding themselves.
As for a real American pharma with money taking a stake or buying AMBS, yes, you are right, BP typically wants some proven P2 results at least. AMBS appears to have some proven P2 results in ESS and some very encouraging small P2 trial results in Elto. In addition, the MANF preclinical literature is spectacular, even profiled in 'Science.' So while you are right that BP usually wants companies with deeper pipes, I don't think it would be out of the realm of possibility for some American pharma with a good cash position, even if not BP, to want to explore a stake/buyout of AMBS. The fact that no one came forward and we are now dealing with Singapore-based SeD and CHF is rather disappointing.
As for a real American pharma with money taking a stake or buying AMBS, yes, you are right, BP typically wants some proven P2 results at least. AMBS appears to have some proven P2 results in ESS and some very encouraging small P2 trial results in Elto. In addition, the MANF preclinical literature is spectacular, even profiled in 'Science.' So while you are right that BP usually wants companies with deeper pipes, I don't think it would be out of the realm of possibility for some American pharma with a good cash position, even if not BP, to want to explore a stake/buyout of AMBS. The fact that no one came forward and we are now dealing with Singapore-based SeD and CHF is rather disappointing.
(1)
(0)